{Reference Type}: Clinical Trial Protocol
{Title}: A randomized controlled trial to evaluate omentum-preserving gastrectomy for patients with T1-T3 gastric cancer.
{Author}: Lu S;Yang ZY;Yan C;Liu WT;Ni ZT;Yao XX;Hua ZC;Feng RH;Zheng YN;Wang ZQ;Sah BK;Chen MM;Zhu ZL;He CY;Li C;Yan M;Zhu ZG;
{Journal}: Future Oncol
{Volume}: 17
{Issue}: 25
{Year}: Sep 2021
{Factor}: 3.674
{DOI}: 10.2217/fon-2021-0240
{Abstract}: Although complete omentectomy is traditionally performed in patients with gastric cancer as part of radical gastrectomy to ensure the elimination of micrometastases, the prognostic value of omentectomy during gastrectomy remains unclear. Retrospective studies have shown that the incidence of metastases in the greater omentum is very low in T1-T3 gastric cancer. Thus radical gastrectomy with D2 lymphadenectomy and preservation of the greater omentum may be a proper curative treatment for gastric cancer patients with T1-T3 tumors. The aim of this article is to describe the design and rationale for this prospective, randomized controlled DRAGON-05 trial, conducted to evaluate the prognostic value of omentum-preserving gastrectomy for patients with T1-T3 gastric cancer. Clinical trial registration: ChiCTR2000040045 (ClinicalTrials.gov).